Logo image of MXCT

MAXCYTE INC (MXCT) Stock Fundamental Analysis

NASDAQ:MXCT - Nasdaq - US57777K1060 - Common Stock - Currency: USD

2.04  -0.02 (-0.97%)

After market: 2.04 0 (0%)

Fundamental Rating

4

Taking everything into account, MXCT scores 4 out of 10 in our fundamental rating. MXCT was compared to 55 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for MXCT as it has an excellent financial health rating, but there are worries on the profitability. MXCT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MXCT had negative earnings in the past year.
In the past year MXCT has reported a negative cash flow from operations.
MXCT had negative earnings in each of the past 5 years.
MXCT had a negative operating cash flow in each of the past 5 years.
MXCT Yearly Net Income VS EBIT VS OCF VS FCFMXCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

MXCT has a Return On Assets (-18.17%) which is comparable to the rest of the industry.
MXCT has a Return On Equity of -20.96%. This is comparable to the rest of the industry: MXCT outperforms 54.55% of its industry peers.
Industry RankSector Rank
ROA -18.17%
ROE -20.96%
ROIC N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
MXCT Yearly ROA, ROE, ROICMXCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

Looking at the Gross Margin, with a value of 80.91%, MXCT belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Gross Margin of MXCT has declined.
MXCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
MXCT Yearly Profit, Operating, Gross MarginsMXCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

8

2. Health

2.1 Basic Checks

MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MXCT has been increased compared to 1 year ago.
MXCT has more shares outstanding than it did 5 years ago.
MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MXCT Yearly Shares OutstandingMXCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MXCT Yearly Total Debt VS Total AssetsMXCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 3.11 indicates that MXCT is not in any danger for bankruptcy at the moment.
MXCT's Altman-Z score of 3.11 is fine compared to the rest of the industry. MXCT outperforms 63.64% of its industry peers.
There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.11
ROIC/WACCN/A
WACC9.02%
MXCT Yearly LT Debt VS Equity VS FCFMXCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

MXCT has a Current Ratio of 12.23. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
MXCT's Current ratio of 12.23 is amongst the best of the industry. MXCT outperforms 94.55% of its industry peers.
MXCT has a Quick Ratio of 11.58. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MXCT (11.58) is better than 94.55% of its industry peers.
Industry RankSector Rank
Current Ratio 12.23
Quick Ratio 11.58
MXCT Yearly Current Assets VS Current LiabilitesMXCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for MXCT have decreased strongly by -14.29% in the last year.
Looking at the last year, MXCT shows a very negative growth in Revenue. The Revenue has decreased by -14.46% in the last year.
MXCT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.31% yearly.
EPS 1Y (TTM)-14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
Revenue 1Y (TTM)-14.46%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-8.39%

3.2 Future

The Earnings Per Share is expected to grow by 1.86% on average over the next years.
The Revenue is expected to grow by 31.33% on average over the next years. This is a very strong growth
EPS Next Y0.62%
EPS Next 2Y1.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.8%
Revenue Next 2Y14.79%
Revenue Next 3Y32.88%
Revenue Next 5Y31.33%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MXCT Yearly Revenue VS EstimatesMXCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M
MXCT Yearly EPS VS EstimatesMXCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MXCT. In the last year negative earnings were reported.
Also next year MXCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MXCT Price Earnings VS Forward Price EarningsMXCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MXCT Per share dataMXCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.86%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MXCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAXCYTE INC

NASDAQ:MXCT (8/1/2025, 8:00:00 PM)

After market: 2.04 0 (0%)

2.04

-0.02 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/amc
Inst Owners71.39%
Inst Owner Change-3.69%
Ins Owners0.83%
Ins Owner Change2.61%
Market Cap217.10M
Analysts87.27
Price Target7.14 (250%)
Short Float %3.49%
Short Ratio4.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.13%
Min EPS beat(2)6.63%
Max EPS beat(2)19.64%
EPS beat(4)4
Avg EPS beat(4)17.29%
Min EPS beat(4)6.63%
Max EPS beat(4)30.34%
EPS beat(8)6
Avg EPS beat(8)15.67%
EPS beat(12)10
Avg EPS beat(12)15.77%
EPS beat(16)14
Avg EPS beat(16)19.21%
Revenue beat(2)2
Avg Revenue beat(2)6.39%
Min Revenue beat(2)5.28%
Max Revenue beat(2)7.51%
Revenue beat(4)4
Avg Revenue beat(4)12.6%
Min Revenue beat(4)5.28%
Max Revenue beat(4)29.09%
Revenue beat(8)6
Avg Revenue beat(8)10.68%
Revenue beat(12)9
Avg Revenue beat(12)6.92%
Revenue beat(16)13
Avg Revenue beat(16)11.19%
PT rev (1m)0%
PT rev (3m)-4.55%
EPS NQ rev (1m)1.59%
EPS NQ rev (3m)-5.98%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.74%
Revenue NQ rev (1m)-0.48%
Revenue NQ rev (3m)-2.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.76
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB 1.11
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.35
BVpS1.87
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.17%
ROE -20.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.91%
FCFM N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.88%
Cap/Sales 3.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.23
Quick Ratio 11.58
Altman-Z 3.11
F-Score2
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)270.47%
Cap/Depr(5y)255.66%
Cap/Sales(3y)18.33%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.11%
EPS Next Y0.62%
EPS Next 2Y1.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-14.46%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-8.39%
Revenue Next Year8.8%
Revenue Next 2Y14.79%
Revenue Next 3Y32.88%
Revenue Next 5Y31.33%
EBIT growth 1Y-6.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.13%
OCF growth 3YN/A
OCF growth 5YN/A